Immunotherapy Combining Nk And T Cell Activation With Il-15 Super Agonist (N-803), Off-The-Shelf High-Affinity Cd16 Nk (Hank) Or Pdl1 Targeted Hank And Checkpoint Inhibitor In Relapsed/Refractory Advanced Pancreatic Cancer.

Tara Elisabeth Seery,Mira Kistler,Chaitali Singh Nangia, Christina Ann To,Sandeep K. Reddy,Leonard S. Sender,John H. Lee,Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 2|浏览48

暂无评分

摘要

e15015Background: Pancreatic cancer is the third leading cause of cancer-related deaths in the US. Patients who relapse after first/second-line chemotherapy have a 2 month median survival. In this ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要